



11 Publication number:

0 401 384
A1

12

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

21 Application number: 90900360.0

 51 Int. Cl.⁵: C07K 13/00, C07K 3/08,
 A61K 37/02

22 Date of filing: 22.12.89

 96 International application number:
 PCT/JP89/01292

 97 International publication number:
 WO 90/06952 (28.06.90 90/15)

 30 Priority: 22.12.88 JP 324747/88
 31.07.89 JP 199176/89

 43 Date of publication of application:
 12.12.90 Bulletin 90/50

 84 Designated Contracting States:
 AT BE CH DE ES FR GB IT LI LU NL SE

 71 Applicant: Kirin-Amgen, Inc.
 1900 Oak Terrace Lane
 Thousand Oaks California 91320(US)

 72 Inventor: ISHIKAWA, Rika
 36-2, Takagi 1-chome Higashiyamato-shi
 Tokyo 189(JP)
 Inventor: OKADA, Yuji
 391, Kamikoide-machi Maebashi-shi
 Gunma-ken 371(JP)
 Inventor: KAKITANI, Makoto
 391, Kamikoide-machi Maebashi-shi
 Gunma-ken 371(JP)

 74 Representative: Brown, John David
 FORRESTER & BOEHMERT
 Widenmayerstrasse 41
 D-8000 München 22(DE)

54 **CHEMICALLY MODIFIED GRANULOCYTE COLONY STIMULATING FACTOR.**

97 This invention provides a chemically modified protein prepared by combining polyethylene glycol with a polypeptide having substantially the following amino acid sequence and comprising the product of manifestation by a host cell of a foreign DNA sequence (1), wherein n is 0 or 1. This protein has a more lasting action of increasing neutrophils than that of the human granulocyte colony stimulating factor (G-CSF) known heretofore.

EP 0 401 384 A1

BEST AVAILABLE COPY